Floatz logo

Lanreotide

Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours

Federation Francophone de Cancerologie Digestiveprotein_peptidePhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours cohort.

Asset / SponsorPhaseRating
Sargramostim
Roswell Park Cancer Institute
Phase 2CCC
Survaxm
Roswell Park Cancer Institute
Phase 2CCC
Ifa
Roswell Park Cancer Institute
Phase 2CCC
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Fudan University
Phase 2CCC
Everolimus
Novartis Pharmaceuticals
Phase 1CC

View all 10 →

Same molecule, other indications

Lanreotide is also rated in:

lymphoceleDormant
BB
Indicative ·
64 / 100
View asset →
malignant endocrine neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
non-functional pancreatic neuroendocrine tumorDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →